<?xml version="1.0" encoding="UTF-8"?>
<results title="virus_topics">
 <result pre="2009, Middle East respiratory syndrome coronavirus (MERS-CoV) since 2012, Ebola" exact="virus" post="in 2013–2016 and from 2018 onward, and Zika virus"/>
 <result pre="Ebola virus in 2013–2016 and from 2018 onward, and Zika" exact="virus" post="in 2015–16 are some examples [ 5– 9]. In"/>
 <result pre="Janssen Vaccines and University of Oxford Lassa US$19.0 million Recombinant" exact="virus" post="Preclinical MERS-CoV Phase I Nipah Preclinical Profectus BioSciences, Emergent"/>
 <result pre="Profectus BioSciences, Emergent BioSolutions, and PATH Lassa US$36.0 million Recombinant" exact="virus" post="Preclinical Nipah US$25.0 million Protein subunit Preclinical International AIDS"/>
 <result pre="Preclinical International AIDS Vaccine Initiative (IAVI) Lassa US$54.9 million Recombinant" exact="virus" post="Preclinical IDT Biologika MERS-CoV US$36.0 million Recombinant virus Phase"/>
 <result pre="million Recombinant virus Preclinical IDT Biologika MERS-CoV US$36.0 million Recombinant" exact="virus" post="Phase I Themis Bioscience Lassa US$58.5 million Recombinant virus"/>
 <result pre="Recombinant virus Phase I Themis Bioscience Lassa US$58.5 million Recombinant" exact="virus" post="Phase I MERS-CoV Preclinical Chikungunya Phase III University of"/>
 <result pre="Chikungunya Phase III University of Tokyo Nipah US$31.0 million Recombinant" exact="virus" post="Phase I Inovio Pharmaceuticals Lassa US$56.0 million DNA Preclinical"/>
 <result pre="Phase II Colorado State University Rift Valley fever US$9.5million Attenuated" exact="virus" post="Preclinical Wageningen Bioveterinary Research Rift Valley fever US$12.5 million"/>
 <result pre="Preclinical Wageningen Bioveterinary Research Rift Valley fever US$12.5 million Attenuated" exact="virus" post="Phase I Valneva Chikungunya US$23.4 million Attenuated virus Phase"/>
 <result pre="million Attenuated virus Phase I Valneva Chikungunya US$23.4 million Attenuated" exact="virus" post="Phase I Public health vaccines Nipah US$43.6 million Recombinant"/>
 <result pre="virus Phase I Public health vaccines Nipah US$43.6 million Recombinant" exact="virus" post="Preclinical Imperial College London Marburg US$8.4 million RNA Preclinical"/>
 <result pre="Queensland MERS-CoV US$10.6 million Recombinant protein Preclinical Influenza Respiratory syncytial" exact="virus" post="The CEPI vaccine portfolio contains a wide variety of"/>
 <result pre="phase I/II and, potentially, phase III efficacy trials, access to" exact="common" post="sets of reference standards will be crucial for the"/>
 <result pre="GL Byahatti SM An insight into the swine-influenza A (H1N1)" exact="virus" post="infection in humans Lung India 2011 28 34 38"/>
 <result pre="9. Pereira AM Monteiro DLM Werner H et al. Zika" exact="virus" post="and pregnancy in Brazil: what happened? J Turk Ger"/>
 <result pre="2019 31. collab: WHO WHO target product profile for Lassa" exact="virus" post="vaccine 2017 32. collab: WHO WHO target product profiles"/>
 <result pre="2017 33. collab: WHO WHO target product profile for Nipah" exact="virus" post="vaccine 2017 34. Brighton Collaboration (2019) https://www.brightoncollaboration.org/. Accessed 28"/>
</results>
